1. Background
2. Objectives
3. Methods
3.1. Study Design and Patients’ Recruitment
3.1.1. Inclusion Criteria
3.1.2. Exclusion Criteria
3.2. Assessment and Data Collection
3.3. Statistical Analysis
4. Results
| GBM (N = 20) | GBN (N = 20) | P Valuec | |
|---|---|---|---|
| Age (years) | 51.1 ± 9.4 | 49.9 ± 9.8 | 0.674 |
| BMI (kg/m2) | 28.6 ± 1.6 | 29.1 ± 1.0 | 0.415 |
| ASA I/II | 9 (45)/11 (55) | 8 (40)/12 (60) | 0.749 |
| Operative time (hours) | 1.7 ± 0.4 | 1.6 ± 0.5 | 0.456 |
Abbreviations: GBM, bupivacaine/magnesium sulphate; GBN, bupivacaine/nalbuphine
aValues are presented as mean ± SD or No. (%)
bNo statistically significant differences between the two groups
cP value < 0.05 is statistically significant
| GBM (N = 20) | GBN (N = 20) | P Valueb | |
|---|---|---|---|
| Sensory block-20 min | 2 (2 - 3) | 2 (2 - 3) | > 0.999 |
| Sensory block-1 h postoperative | 2 (2 - 3) | 2 (2 - 3) | > 0.999 |
| Sensory block-6 h post | 2 (2 - 3) | 2 (2 - 3) | > 0.999 |
| Sensory block-12 h post | 2 (1 - 2) | 2 (1 - 2) | 0.190 |
| Sensory block-24 h post | 1 (1 - 1) | 1 (1 - 2) | 0.004c |
| The Medical Research Council Scal-20 min | 4 (3 - 5) | 4 (3 - 5) | 0.133 |
| The Medical Research Council Scal-1 h postoperative | 4 (3 - 5) | 4 (3 - 5) | 0.174 |
| The Medical Research Council Scal-6 h post | 5 (4 - 5) | 4 (4 - 5) | 0.118 |
| The Medical Research Council Scal-12 h post | 5 (3 - 5) | 5 (3 - 5) | 0.054 |
| The Medical Research Council Scal-24 hpost | 5 (5 - 5) | 4 (4 - 5) | < 0.001c |
Abbreviations: GBM, bupivacaine/magnesium sulphate; GBN, bupivacaine/nalbuphine
aValues are presented as median (range).
bP value < 0.05 is statistically significant.
cStatistically significant difference.
| GBM (N = 20) | GBN (N = 20) | P Valueb | |
|---|---|---|---|
| Fentanyl (ug) | 100.0 ± 0.0 | 100.0 ± 0.0 | > 0.999 |
| TFA hours | 20.3 ± 2.3 | 22.1 ± 2.0 | 0.010c |
| Pethidine mg/24 h | 30.0 ± 25.1 | 20.0 ± 25.1 | 0.212 |
| VAS Rest-1 h post | 3 (1-4) | 2 (1-4) | 0.260 |
| VAS Rest-6 h post | 3 (1-4) | 2.5 (1-4) | 0.019c |
| VAS Rest-12 h post | 3 (1-5) | 3 (2-4) | 0.676 |
| VAS Rest-24 h post | 4 (3-5) | 3 (2-5) | < 0.001c |
| VAS Mov.-1 h post | 4 (2-5) | 3 (2-5) | 0.353 |
| VAS Mov.-6 h post | 4 (3-5) | 4 (2-5) | 0.470 |
| VAS Mov.-12 h post | 4.5 (3-5) | 4 (2-5) | 0.096 |
| VAS Mov.-24 h post | 3 (4-5) | 2 (3-5) | 0.068 |
Abbreviations: GBM, bupivacaine/magnesium sulphate; GBN, bupivacaine/nalbuphine
aValues are presented as mean ± SD or median (range).
bP value < 0.05 is statistically significant.
cStatistically significant difference.
| GBM (N = 20) | GBN (N = 20) | P Valuec | |
|---|---|---|---|
| Heart rate 1 h post | 79.4 ± 9.7 | 76.8 ± 6.7 | 0.343 |
| Heart rate 6 h post | 78.8 ± 9.1 | 74.3 ± 5.8 | 0.560 |
| Heart rate 12 h post | 77.9 ± 7.2 | 76.1 ± 6.5 | 0.604 |
| Heart rate 24 h post | 77.8 ± 8.7 | 76.0 ± 6.7 | 0.125 |
Abbreviations: GBM, bupivacaine/magnesium sulfate; GBN, bupivacaine/nalbuphine
aValues are presented as mean ± SD.
bNo statistically significant differences between the two groups.
cP value < 0.05 is statistically significant.
| GBM (N = 20) | GBN (N = 20) | P Valuec | |
|---|---|---|---|
| MAP 1 h post | 92.5 ± 5.5 | 91.3 ± 6.8 | 0.604 |
| MAP 6 h post | 91.2 ± 7.4 | 89.5 ± 6.2 | 0.125 |
| MAP 12 h post | 92.6 ± 7.8 | 90.3 ± 7.8 | 0.321 |
| MAP 24 h post | 92.1 ± 7.8 | 88.9 ± 7.1 | 0.192 |
Abbreviations: GBM, bupivacaine/magnesium sulfate; GBN, bupivacaine/nalbuphine
aValues are presented as mean ± SD.
bNo statistically significant differences between the two groups.
cP value < 0.05 is statistically significant.
